S&P 500   3,367.50 (-0.37%)
DOW   29,197.54 (-0.68%)
QQQ   234.46 (-0.08%)
AAPL   318.24 (-2.06%)
FB   217.20 (+1.41%)
GOOGL   1,517.92 (-0.05%)
AMZN   2,157.32 (+1.05%)
NVDA   292.86 (+1.06%)
BABA   219.65 (+0.01%)
MU   57.85 (-1.11%)
TSLA   849.48 (+6.18%)
AMD   57.09 (+3.22%)
ACB   1.63 (+3.16%)
F   8.04 (-0.74%)
NFLX   388.28 (+2.07%)
BAC   34.15 (-2.01%)
DIS   138.48 (-0.76%)
GILD   67.05 (-0.75%)
S&P 500   3,367.50 (-0.37%)
DOW   29,197.54 (-0.68%)
QQQ   234.46 (-0.08%)
AAPL   318.24 (-2.06%)
FB   217.20 (+1.41%)
GOOGL   1,517.92 (-0.05%)
AMZN   2,157.32 (+1.05%)
NVDA   292.86 (+1.06%)
BABA   219.65 (+0.01%)
MU   57.85 (-1.11%)
TSLA   849.48 (+6.18%)
AMD   57.09 (+3.22%)
ACB   1.63 (+3.16%)
F   8.04 (-0.74%)
NFLX   388.28 (+2.07%)
BAC   34.15 (-2.01%)
DIS   138.48 (-0.76%)
GILD   67.05 (-0.75%)
S&P 500   3,367.50 (-0.37%)
DOW   29,197.54 (-0.68%)
QQQ   234.46 (-0.08%)
AAPL   318.24 (-2.06%)
FB   217.20 (+1.41%)
GOOGL   1,517.92 (-0.05%)
AMZN   2,157.32 (+1.05%)
NVDA   292.86 (+1.06%)
BABA   219.65 (+0.01%)
MU   57.85 (-1.11%)
TSLA   849.48 (+6.18%)
AMD   57.09 (+3.22%)
ACB   1.63 (+3.16%)
F   8.04 (-0.74%)
NFLX   388.28 (+2.07%)
BAC   34.15 (-2.01%)
DIS   138.48 (-0.76%)
GILD   67.05 (-0.75%)
S&P 500   3,367.50 (-0.37%)
DOW   29,197.54 (-0.68%)
QQQ   234.46 (-0.08%)
AAPL   318.24 (-2.06%)
FB   217.20 (+1.41%)
GOOGL   1,517.92 (-0.05%)
AMZN   2,157.32 (+1.05%)
NVDA   292.86 (+1.06%)
BABA   219.65 (+0.01%)
MU   57.85 (-1.11%)
TSLA   849.48 (+6.18%)
AMD   57.09 (+3.22%)
ACB   1.63 (+3.16%)
F   8.04 (-0.74%)
NFLX   388.28 (+2.07%)
BAC   34.15 (-2.01%)
DIS   138.48 (-0.76%)
GILD   67.05 (-0.75%)
Log in

NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range
$18.00
MA: $18.00
$18.00
52-Week Range N/A
Volume303,068 shs
Average Volume2.56 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.


Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) posted its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.25 by $0.02. The biopharmaceutical company had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. The business's revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.30 EPS. View Sucampo Pharmaceuticals' Earnings History.

Has Sucampo Pharmaceuticals been receiving favorable news coverage?

Media coverage about SCMP stock has trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sucampo Pharmaceuticals earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future. View News Stories for Sucampo Pharmaceuticals.

Who are some of Sucampo Pharmaceuticals' key competitors?

What other stocks do shareholders of Sucampo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sucampo Pharmaceuticals investors own include XOMA (XOMA), Sprint (S), Alnylam Pharmaceuticals (ALNY), Xenon Pharmaceuticals (XENE), Teekay Tankers (TNK), Gilead Sciences (GILD), Micron Technology (MU), Opko Health (OPK), Cisco Systems (CSCO) and Infinera (INFN).

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:
  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

What is Sucampo Pharmaceuticals' official website?

The official website for Sucampo Pharmaceuticals is http://www.sucampo.com/.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  300 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  577
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel